Trials / Completed
CompletedNCT05486195
A Single Ascending Oral Dose Study of SDI-118 in Healthy Male Subjects Including an Assessment of Receptor Occupancy and Food Effect
A First-in-Human, Randomized, Placebo-controlled, Single Ascending Oral Dose Study of SDI-118 in Healthy Male Subjects Including Receptor Occupancy Measurements After Single Dose of SDI-118 and an Assessment of Food Effect
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- Male
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
This is a First-in-Human, Randomized, Placebo-controlled, Single Ascending Oral Dose Study of SDI-118 in Healthy Male Subjects including Receptor Occupancy Measurements after Single Dose of SDI-118 and an Assessment of Food Effect.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SDI-118 | SDI-118 Powder in Capsule |
| DRUG | Placebo | Matching Placebo |
Timeline
- Start date
- 2019-03-14
- Primary completion
- 2019-07-29
- Completion
- 2020-03-11
- First posted
- 2022-08-03
- Last updated
- 2022-08-03
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT05486195. Inclusion in this directory is not an endorsement.